|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exercise intervention attenuates neuropathic pain in diabetes via mechanisms of mammalian target of rapamycin (mTOR).
|
30317878 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The functional interplay between the ISR and mTOR may have significant ramifications in the development and treatment of human diseases such as diabetes, neurodegeneration and cancer.
|
30572003 |
2019 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Second, we found that molecular activation of small intestinal mTOR blunts the glucose-lowering effect of the oral anti-diabetic agent metformin, while inhibiting small intestinal mTOR alone lowers plasma glucose levels by inhibiting glucose production in rodents with diabetes as well.
|
30755615 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of malondialdehyde and TGF-β1/PI3K/Akt/mTOR pathway activation were increased in the renal cortex of rats with diabetes compared with the control rats.
|
30651870 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence has suggested a master role of mTOR signalling in many fundamental aspects of cell biology and organismal development. mTOR deregulation is implicated in a broad range of pathological conditions, including diabetes, cancer, neurodegenerative diseases, myopathies, inflammatory, infectious, and autoimmune conditions.
|
29768134 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hyperactivity of the mTOR pathway is associated with numerous human diseases, including diabetes, cancer and epilepsy.
|
31722960 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our discovery of autophagy as a link between MTOR and GABA signaling may have implications not limited to neurodevelopmental and neuropsychiatric disorders, but could potentially be involved in other human pathologies such as cancer and diabetes in which both pathways are implicated.
|
31280658 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modulation of mTOR function to increase autophagy and inhibit apoptosis is involved in the protective effects of pharmacologic agents targeting diabetes and Alzheimer's disease (AD).
|
30684442 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A. Unmasking the interplay between mTOR and Nox4: novel insights into the mechanism connecting diabetes and cancer.
|
31661292 |
2019 |
|
Diabetes
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Diabetes may reduce the phosphorylation of adenosine 5'-monophosphate activated protein kinase (AMPKα) and increase the phosphorylation of mTOR to attenuate cardioprotection of remote postconditioning.
|
30729392 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mammalian target of rapamycin (mTOR) regulates cell proliferation and mitochondrial function. mTOR inhibitors (e.g., rapamycin) are used clinically to prevent graft rejection. mTOR has been identified as a key player in diabetes, which has stimulated the use of mTOR inhibitors to counter diabetic nephropathy.
|
28971989 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysregulation of mTOR occurs in diabetes, cancer and neurological disease.
|
29424687 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mammalian target of rapamycin (mTOR) has been associated with glucose metabolism, diabetes, and altering BBB permeability.
|
28625574 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Drugs that induce diabetes include hormonal therapy, especially glucocorticoids and androgen blockers, cardiovascular drugs, especially statins, beta-blockers and diuretics, antipsychotics, especially clozapine, olanzapine and quetiapine, antiretrovirals (protease inhibitors and non-reverse transcriptase inhibitors - NRTIs) and other drugs (mechanistic target of rapamycin inhibitors -mTORs, post organ transplantation drugs, tyrosine kinase inhibitors and interferon-alpha).
|
28923179 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that mice lacking the core nutrient-sensitive signaling component mammalian target of rapamycin (mTOR) in β cells exhibit reduced β cell mass and smaller islets. mTOR deficiency leads to a severe reduction in β cell survival and increased mitochondrial oxidative stress in chemical-induced diabetes.
|
28606928 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extensive research over the past two decades has established a central role for mTOR in regulating many fundamental cell processes, from protein synthesis to autophagy, and deregulated mTOR signaling is implicated in the progression of cancer and diabetes, as well as the aging process.
|
28283069 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
In June 2013, the National Institute of Diabetes and Digestive and Kidney Diseases convened a small panel of physicians and scientists working in the field to identify key unknowns and define possible "next steps" in advancing understanding of TSC- and mTOR-dependent renal phenotypes.
|
24226526 |
2014 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mammalian target of rapamycin (mTOR) is an evolutionarily conserved protein kinase. mTOR forms two distinct functional multiprotein kinase complexes that mutually phosphorylate different substrates and regulate a wide array of essential cellular processes including translation, transcription and autophagy. mTOR is active in several types of cancer and plays a role in a variety of other serious human diseases, including diabetes, neurodegenerative disorders and polycystic kidney disease.
|
22388550 |
2012 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanistic target of rapamycin (mTOR) kinase controls growth and metabolism, and its deregulation underlies the pathogenesis of many diseases, including cancer, neurodegeneration, and diabetes. mTOR complex 1 (mTORC1) integrates signals arising from nutrients, energy, and growth factors, but how exactly these signals are propagated await to be fully understood.
|
22749019 |
2012 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similarly, enhanced mammalian target of rapamycin (mTOR) activation has been implicated in mesangial matrix expansion and glomerular hypertrophy in diabetes.
|
21613414 |
2011 |